Xin Lang Cai Jing·2025-08-01 07:52Core Viewpoint - Haiprime, a leading multinational pharmaceutical company, is benefiting from the depreciation of the RMB and its focus on innovative drugs and biopharmaceuticals [2][3]. Company Overview - Established in 1998 in Shenzhen, Haiprime operates with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2]. - The company reported that 93.04% of its revenue comes from overseas, benefiting from the depreciation of the RMB [3]. - As of March 31, 2025, Haiprime's revenue reached 1.394 billion yuan, a year-on-year increase of 1.53%, with a net profit of 157 million yuan, up 1.00% [7]. Financial Performance - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. - The average trading cost of Haiprime's shares is 11.29 yuan, with the current stock price fluctuating between resistance at 13.88 yuan and support at 12.41 yuan [6]. Market Activity - On August 1, Haiprime's stock fell by 1.05%, with a trading volume of 111 million yuan and a turnover rate of 0.66%, bringing the total market capitalization to 19.442 billion yuan [1]. - The main capital flow showed a net outflow of 5.9454 million yuan, indicating a reduction in main capital positions over the past three days [4][5].